The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s demonstrating significant promise in clinical trials for addressing obesity. Unlike some available weight loss treatments, retatrutide appears to provide a significant substantial reduction in body weight and enhance metabolic